← Leaderboards
Arindam Sen
Buffalo Biolabs, Llc
$486,212
Attributed
$486,212
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $208.1K · FY2009–16$250K$187.5K$125K$62.5K$0
'09
'10
'11
'12
'13
'14
'15
'16
Funding mix
By agency
NIH$486,212 · 2
By mechanism
R21$381,604 · 1
R41$104,608 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsBaseCancer CellPlayIn VivoCancer TherapyNeoplastic CellTumorBlood FlowBiologicalEndothelial CellsCancer ControlCancer PatientCancer PrognosisEndotheliumCytokineCardiac OutputDisease-Free SurvivalCancer SurvivorCellsBreast CarcinomaBody TemperatureBlood VesselsCancer Stem Cell
Grant awards (3)
(PQA2) A NEW TOOL FOR CANCER PROGNOSTICATION BASED ON ALTERING VASCULAR HOMOEOSTASIS$173,456
R21 · FY2016 · CA · contact PI
(PQA2) A NEW TOOL FOR CANCER PROGNOSTICATION BASED ON ALTERING VASCULAR HOMOEOSTASIS$208,148
R21 · FY2015 · CA · contact PI
Safety/Efficacy of Liposomal Reversan, a novel MRP1 modulator for Cancer Therapy$104,608
R41 · FY2009 · CA · contact PI